First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

August 31, 2022

Study Completion Date

November 30, 2023

Conditions
Ewing Sarcoma Family of Tumors
Interventions
DRUG

VDC-IE x2

"Week 1, 5, 9 and week 13:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"

DRUG

VDC-IE

"Week 1 and week 5:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"

DRUG

TEMIRI

"Week 9, 12, 15 and week 18:~* Temozolomide, PO, D1 to D5, 150mg/m²/d~* Irinotecan, IV, D1 to D5, 50mg/m²/d"

DRUG

Consolidation BuMel

"After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~\- PBSC infusion, D0, at least 3.10\^6 CD34/kg"

DRUG

Maintenance

"\* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously"

PROCEDURE

Local treatment by surgery

Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added

RADIATION

Local treatment by radiotherapy

Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy

Trial Locations (17)

13000

Marseille Chu, Marseille

31059

Toulouse Chu, Toulouse

TOULOUSE Institut Claudius Regaud, Toulouse

33076

Bordeaux Chu, Bordeaux

34295

CHRU Montpellier - Hôpital A. de Villeneuve, Montpellier

35056

CHU Hôpital Sud, Rennes

38043

CHU Grenoble Alpes, Grenoble

44000

Nantes Chu, Nantes

54511

Nancy Chu, Vandœuvre-lès-Nancy

54519

NANCY Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

59000

LILLE Centre Oscar Lambret, Lille

67098

Strasbourg Chu, Strasbourg

69000

LYON Centre Léon Bérard, Lyon

75005

PARIS Institut Curie, Paris

75012

PARIS Trousseau, Paris

94805

VILLEJUIF Institut Gustave Roussy, Villejuif

97400

Chr Felix Guyon, La Réunion

All Listed Sponsors
collaborator

UNICANCER

OTHER

lead

Institut Curie

OTHER

NCT03011528 - First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3) | Biotech Hunter | Biotech Hunter